Goldman Sachs called the device’s launch at AT&T Inc. (T) stores “disappointing” and cut the stock to neutral from buy ... Office has decided against Idenix Pharmaceuticals Inc. (IDIX) in the first phase of a two-stage interference process ...
Billionaires Portfolio: This week the biotech stock Idenix Pharmaceuticals Inc (NASDAQ:IDIX) was acquired by Merck …
Here are the top stories from the stock market today: 1. Deals, deals, deals in pharma and meats: Merck announced earlier this morning that it was going to acquire Idenix Pharmaceuticals (IDIX), a hepatitis C drug producer for $24.50 a …
Idenix Pharmaceuticals (IDIX): Deutsche Bank begins Buy rated research. Vodafone (VOD): The telecom titan is resumed with an Outperform at Robert W. Baird, which issues a price objective of $30 on a stock it says is attractively exposed …
The stock has gained 1.4% over the last year. 10. Idenix Pharmaceuticals Inc. (IDIX): Biotechnology Industry. Market cap of $581.71M. Beta at 0.23. Net insider shares purchased over the last six months at 38.08K, which is 0.06% of the …
Idenix Pharmaceuticals (NASDAQ: IDIX) and Spectrum Pharmaceuticals (NASDAQ ... The company also recently announced a stock offering. Idenix is headquartered in Cambridge, Mass., and develops drugs for the treatment of …
Idenix /quotes/zigman/90571/delayed /quotes/nls/idix IDIX is a biopharmaceutical company that specializes ... for Gilead’s /quotes/zigman/72849/delayed /quotes/nls/gild GILD stock given the greater credibility and resources that …
The company stock has a 52-week trading average of $25.00-$42.78 and a market capitalization of $2.24 billion. Idenix …
agreed to pay $3.85 billion in cash for biotech Idenix (IDIX), an unprofitable developer of a hepatitis C drug. The deal valued Idenix at ... wait for it ... a nearly 240% premium to its Friday closing price. Take a minute and think about that. The …